查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1370961

非侵入性產前檢測市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按產品類型、測試類型、方法、按應用、最終用戶、地區和競爭細分

Non-invasive Prenatal Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product Type, By Test Type, By Method, By Application, By End User, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 171 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022年全球非侵入性產前檢測（NIPT）市場估值達40.3億美元，並預計在整個預測期內大幅成長，年複合成長率（CAGR）為7.38%，預計將達到61.6億美元至2028 年。無創產前檢測是一種革命性的產前篩檢方法，需要分析孕婦的血液樣本以識別潛在的胎兒異常。這項先進技術主要用於診斷唐氏症（21 三體症）、愛德華茲氏症候群（18 三體）、帕陶氏症候群（13 三體症）和特納氏症等遺傳性疾病，涉及檢查母體血液中的DNA 片段。值得注意的是，該程序消除了絨毛膜絨毛取樣（CVS）等侵入性過程的需要，提供了更安全的替代方案，並且可以在懷孕第九週後進行。

主要市場促進因素

越來越重視早期發現與預防

市場概況
預測期 2024-2028
2022 年市場規模 40.3億美元
2028 年市場規模 61.6億美元
2023-2028 年年複合成長率 7.38%
成長最快的細分市場 微缺失症候群
最大的市場 北美洲

對早期檢測和預防的日益關注極大地刺激了對非侵入性產前檢測 (NIPT) 的需求。這種開創性的篩檢技術能夠透過簡單的母體血液檢測來識別發育中胎兒的特定遺傳異常，這不同於羊膜穿刺術或絨毛膜絨毛取樣（CVS）等傳統的侵入性方法，這些方法具有流產的風險。 NIPT 是一種更安全的替代方案，可提供可靠的早期基因篩檢。

先進篩選技術的可用性

基因組定序技術的進步，特別是次世代定序 (NGS)，簡化了診斷流程，縮短了周轉時間。這些進步促進了非侵入性診斷的發展，從而能夠準確檢測各種遺傳性疾病。再加上基於 NGS 的 NIPT 測試的成長，增強了業界在保持競爭力的同時提供精確結果的能力。

醫療保健報銷政策向基因覆蓋的轉變

報銷政策的改變對於提高醫療服務的可負擔性和可近性發揮關鍵作用。使 NIPT 對患者在經濟上可行的調整可以提高採用率。與傳統方法相比，NIPT 的非侵入性和準確性使其成為準父母的一個有吸引力的選擇。當 NIPT 費用由保險承擔時，它就成為更廣泛的個人的可行選擇。

遺傳和先天性疾病的盛行率不斷增加

遺傳和先天性疾病盛行率的不斷上升極大地增加了對 NIPT 的需求。隨著意識的增強以及對家庭的影響變得顯而易見，未來的父母​​會尋求各種方法來確保未出生孩子的福祉。 NIPT 作為一種非侵入性且準確的早期檢測方法，已成為高風險族群的首選。

主要市場挑戰

NIPT 的局限性

儘管 NIPT 準確度很高，但仍存在假陽性或假陰性結果的可能性。這種不確定性可能會讓患者對完全依賴 NIPT 做出診斷決策猶豫不決。此外，NIPT 是一種篩檢測試，需要後續侵入性診斷來確認陽性結果。

替代篩選和測試方法

傳統的血清篩檢測試、序貫篩檢和羊膜穿刺術或 CVS 等侵入性方法由於熟悉度、建議或對準確性的看法可能仍然受到青睞。對 NIPT 益處的認知差距可能會使患者轉向替代方案。

主要市場趨勢

直接面對消費者測試的可用性

直接面對消費者 (DTC) NIPT 檢測的可用性有可能大幅提升需求。 DTC 檢測使個人無需醫療中介即可獲得基因檢測服務。儘管存在擔憂，但 DTC 測試可以提高 NIPT 的認知度、可及性和利用率。

專注於植入前基因診斷

植入前遺傳學診斷 (PGD) 和 NIPT 相結合，可在植入前和植入後提供全面的遺傳健康評估。 NIPT 可以驗證 PGD 結果並為父母提供有關遺傳健康的保證。

細分市場洞察

產品類型見解

在產品類型細分市場中，三體性條件占主導地位，NIPT 成為檢測21、18 和13 三體性的有效方法。該方法在體外受精(IVF) 懷孕中的卓越敏感性和特異性進一步增強了其重要性。

最終使用者見解

由於患者和醫療保健專業人員對 NIPT 的偏好不斷增加，診斷實驗室在最終用戶類別中處於領先地位。檢測量的激增和安全產前檢測措施促進了該細分市場的成長。

區域洞察

到 2022 年，在基因檢測、先進研究框架和報銷支援需求的推動下，北美將佔據最大的市場佔有率。歐洲緊隨其後，因為唐氏症的盛行率很高，而且高齡產婦的生育率也很高。由於遺傳因素懷孕人數激增和政府舉措，預計亞太地區將快速成長。

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球非侵入性產前檢測 (NIPT) 市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品類型（消耗品、儀器）
    • 依測試類型（Materni 21、Harmony、Panaroma、Verifi、NIFTY、其他）
    • 依方法（超音波檢測、生化篩檢測試、無細胞 DNA 母體血漿檢驗、母體血液中的胎兒細胞檢驗、其他）
    • 按應用（三體、微缺失症候群、其他）
    • 按最終使用者（診斷實驗室、醫院、其他）
    • 按地區
    • 按公司分類 (2022)
  • 市場地圖

第 6 章：北美非侵入性產前檢測 (NIPT) 市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品類型
    • 按測試類型
    • 依方法
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第 7 章：歐洲非侵入性產前檢測 (NIPT) 市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品類型
    • 按測試類型
    • 依方法
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • 歐洲：國家分析
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙

第 8 章：亞太地區非侵入性產前檢測 (NIPT) 市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品類型
    • 按測試類型
    • 依方法
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 9 章：南美洲無創產前檢測 (NIPT) 市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品類型
    • 按測試類型
    • 依方法
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲非侵入性產前檢測 (NIPT) 市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品類型
    • 按測試類型
    • 依方法
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • MEA：國家分析
    • 南非無創產前檢測 (NIPT)
    • 沙烏地阿拉伯無創產前檢測 (NIPT)
    • 阿拉伯聯合大公國無創產前檢測 (NIPT)

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 近期發展
  • 併購
  • 產品發布

第 13 章：全球口腔臨床營養市場：SWOT 分析

第 14 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第15章：競爭格局

  • 商業概覽
  • 服務內容
  • 最近的發展
  • 主要人員
  • SWOT分析
    • YOURGENE HEALTH Plc
    • Illumina, Inc.
    • Natera, Inc.
    • F.Hoffman La Roche Ltd.
    • Perkin Elmer Inc.
    • Laboratory Corporation of America Holdings
    • Eurofins LifeCodex GmbH
    • Progenity, Inc.
    • Genesis Genetics
    • Quest Diagnostics Incorporated

第 16 章：策略建議

第 17 章：關於我們與免責聲明

簡介目錄
Product Code: 4669

The Global Non-Invasive Prenatal Testing (NIPT) Market achieved a valuation of USD 4.03 Billion in 2022 and is poised for substantial growth throughout the forecast period, exhibiting a Compound Annual Growth Rate (CAGR) of 7.38% and expected to reach USD 6.16 Billion through 2028. Non-Invasive Prenatal Testing is a revolutionary prenatal screening method that entails analyzing a pregnant woman's blood sample to identify potential fetal abnormalities. This advanced technique, primarily employed to diagnose genetic disorders like Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), Patau syndrome (trisomy 13), and Turner syndrome, involves scrutinizing DNA fragments within the maternal blood. Remarkably, this procedure eliminates the need for invasive processes such as chorionic villus sampling (CVS), providing a safer alternative and can be administered after the ninth week of pregnancy.

Key Market Drivers

Increasing Emphasis on Early Detection and Prevention

Market Overview
Forecast Period2024-2028
Market Size 2022USD 4.03 Billion
Market Size 2028USD 6.16 Billion
CAGR 2023-20287.38%
Fastest Growing SegmentMicrodeletion Syndrome
Largest MarketNorth America

A rising focus on early detection and prevention has significantly fueled the demand for Non-Invasive Prenatal Testing (NIPT). This pioneering screening technique enables the identification of specific genetic abnormalities in a developing fetus through a straightforward maternal blood test, diverging from conventional invasive approaches like amniocentesis or chorionic villus sampling (CVS), which carry the risk of miscarriage. NIPT stands out as a safer alternative, offering reliable early genetic screening.

Availability of Advanced Screening Technologies

Advancements in genome sequencing technologies, particularly Next-Generation Sequencing (NGS), have streamlined diagnosis processes with reduced turnaround time. These advances facilitate the development of non-invasive diagnostics, enabling accurate detection of various genetic disorders. This, coupled with the growth of NGS-based NIPT tests, strengthens the industry's capability to provide precise results while maintaining competitiveness.

Healthcare Shift in Reimbursement Policies Towards Genetic Coverage

Alterations in reimbursement policies play a pivotal role in enhancing the affordability and accessibility of medical services. Adjustments that render NIPT financially feasible for patients can lead to heightened adoption rates. The non-invasive nature and accuracy of NIPT, as compared to traditional methods, position it as an appealing option for expectant parents. When NIPT costs are covered by insurance, it becomes a viable choice for a broader spectrum of individuals.

Increasing Prevalence of Genetic and Congenital Disorders

The escalating prevalence of genetic and congenital disorders significantly contributes to the demand for NIPT. As awareness grows and the impact on families becomes apparent, prospective parents seek means to ensure the well-being of their unborn children. NIPT, as a non-invasive and accurate method for early detection, emerges as a preferred choice for those at higher risk.

Key Market Challenges

Limitations of NIPT

Despite its high accuracy, there remains a possibility of false-positive or false-negative results in NIPT. This uncertainty might create hesitancy among patients in fully relying on NIPT for diagnostic decisions. Additionally, NIPT is a screening test, necessitating follow-up invasive diagnostics to confirm positive results.

Alternative Screening and Testing Methods

Traditional serum screening tests, sequential screening, and invasive methods like amniocentesis or CVS might still be favored due to familiarity, recommendations, or perceptions about accuracy. Awareness gaps about the benefits of NIPT might divert patients towards alternatives.

Key Market Trends

Availability of Direct-to-Consumer Tests

The availability of Direct-to-Consumer (DTC) NIPT tests holds the potential to substantially elevate demand. DTC testing empowers individuals to access genetic testing services without medical intermediaries. While concerns exist, DTC testing can augment awareness, accessibility, and utilization of NIPT.

Focus on Pre-Implantation Genetic Diagnosis

The combination of Pre-Implantation Genetic Diagnosis (PGD) and NIPT presents comprehensive genetic health assessment both pre- and post-implantation. NIPT can validate PGD results and provide assurance to parents regarding genetic health.

Segmental Insights

Product Type Insights

Within the product type segment, trisomy conditions dominate, and NIPT emerges as an effective method for detecting trisomy 21, 18, and 13. The method's exceptional sensitivity and specificity in pregnancies resulting from in-vitro fertilization (IVF) further bolster its significance.

End User Insights

Diagnostic laboratories lead the end-user category due to increased preference for NIPT among both patients and healthcare professionals. The surge in test volumes and initiatives for safe prenatal testing contribute to this segment's growth.

Regional Insights

In 2022, North America holds the largest market share, propelled by demand for genetic testing, advanced research framework, and reimbursement support. Europe follows due to high prevalence of Down syndrome and increased childbearing at advanced maternal ages. Asia Pacific is projected for rapid growth due to a surge in pregnancies with genetic conditions and governmental initiatives.

Key Market Players

  • YOURGENE HEALTH Plc
  • Illumina, Inc.
  • Natera, Inc.
  • F.Hoffman La Roche Ltd.
  • Perkin Elmer Inc.
  • Laboratory Corporation of America Holdings
  • Eurofins LifeCodex GmbH
  • Progenity, Inc.
  • Genesis Genetics
  • Quest Diagnostics Incorporated

Report Scope:

In this report, the Global Non-invasive Prenatal Testing (NIPT) Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

Non-invasive Prenatal Testing (NIPT) Market, By Product Type:

  • Consumables
  • Instruments

Non-invasive Prenatal Testing (NIPT) Market, By Test Type:

  • Materni 21
  • Harmony
  • Panaroma
  • Verifi
  • NIFTY
  • Others

Non-invasive Prenatal Testing (NIPT) Market, By Method:

  • Ultrasound Detection
  • Biochemical Screening Testing
  • Cell-Free DNA Maternal Plasma Tests
  • Fetal Cells in Maternal Blood Tests
  • Others

Non-invasive Prenatal Testing (NIPT) Market, By Application:

  • Trisomy
  • Microdeletion Syndrome
  • Others

Non-invasive Prenatal Testing (NIPT) Market, By End User:

  • Diagnostic Laboratories
  • Hospitals
  • Others

Non-invasive Prenatal Testing (NIPT) Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Turkey
  • Egypt

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Non-invasive Prenatal Testing (NIPT) Market.

Available Customizations:

  • Global Non-invasive Prenatal Testing (NIPT) market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Non-invasive Prenatal Testing (NIPT) Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Consumables, Instruments)
    • 5.2.2. By Test Type (Materni 21, Harmony, Panaroma, Verifi, NIFTY, Others)
    • 5.2.3. By Method (Ultrasound Detection, Biochemical Screening Testing, Cell-Free DNA Maternal Plasma Tests, Fetal Cells in Maternal Blood Tests, Others)
    • 5.2.4. By Application (Trisomy, Microdeletion Syndrome, Others)
    • 5.2.5. By End User (Diagnostic Laboratories, Hospitals, Others)
    • 5.2.6. By Region
    • 5.2.7. By Company (2022)
  • 5.3. Market Map

6. North America Non-invasive Prenatal Testing (NIPT) Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Test Type
    • 6.2.3. By Method
    • 6.2.4. By Application
    • 6.2.5. By End User
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Test Type
        • 6.3.1.2.3. By Method
        • 6.3.1.2.4. By Application
        • 6.3.1.2.5. By End User
    • 6.3.2. Canada Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Test Type
        • 6.3.2.2.3. By Method
        • 6.3.2.2.4. By Application
        • 6.3.2.2.5. By End User
    • 6.3.3. Mexico Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Test Type
        • 6.3.3.2.3. By Method
        • 6.3.3.2.4. By Application
        • 6.3.3.2.5. By End User

7. Europe Non-invasive Prenatal Testing (NIPT) Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Test Type
    • 7.2.3. By Method
    • 7.2.4. By Application
    • 7.2.5. By End User
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Test Type
        • 7.3.1.2.3. By Method
        • 7.3.1.2.4. By Application
        • 7.3.1.2.5. By End User
    • 7.3.2. United Kingdom Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Test Type
        • 7.3.2.2.3. By Method
        • 7.3.2.2.4. By Application
        • 7.3.2.2.5. By End User
    • 7.3.3. Italy Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Test Type
        • 7.3.3.2.3. By Method
        • 7.3.3.2.4. By Application
        • 7.3.3.2.5. By End User
    • 7.3.4. France Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By Test Type
        • 7.3.4.2.3. By Method
        • 7.3.4.2.4. By Application
        • 7.3.4.2.5. By End User
    • 7.3.5. Spain Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By Test Type
        • 7.3.5.2.3. By Method
        • 7.3.5.2.4. By Application
        • 7.3.5.2.5. By End User

8. Asia-Pacific Non-invasive Prenatal Testing (NIPT) Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Test Type
    • 8.2.3. By Method
    • 8.2.4. By Application
    • 8.2.5. By End User
    • 8.2.6. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Test Type
        • 8.3.1.2.3. By Method
        • 8.3.1.2.4. By Application
        • 8.3.1.2.5. By End User
    • 8.3.2. India Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Test Type
        • 8.3.2.2.3. By Method
        • 8.3.2.2.4. By Application
        • 8.3.2.2.5. By End User
    • 8.3.3. Japan Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Test Type
        • 8.3.3.2.3. By Method
        • 8.3.3.2.4. By Application
        • 8.3.3.2.5. By End User
    • 8.3.4. South Korea Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By Test Type
        • 8.3.4.2.3. By Method
        • 8.3.4.2.4. By Application
        • 8.3.4.2.5. By End User
    • 8.3.5. Australia Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By Test Type
        • 8.3.5.2.3. By Method
        • 8.3.5.2.4. By Application
        • 8.3.5.2.5. By End User

9. South America Non-invasive Prenatal Testing (NIPT) Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Test Type
    • 9.2.3. By Method
    • 9.2.4. By Application
    • 9.2.5. By End User
    • 9.2.6. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Test Type
        • 9.3.1.2.3. By Method
        • 9.3.1.2.4. By Application
        • 9.3.1.2.5. By End User
    • 9.3.2. Argentina Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Test Type
        • 9.3.2.2.3. By Method
        • 9.3.2.2.4. By Application
        • 9.3.2.2.5. By End User
    • 9.3.3. Colombia Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Test Type
        • 9.3.3.2.3. By Method
        • 9.3.3.2.4. By Application
        • 9.3.3.2.5. By End User

10. Middle East and Africa Non-invasive Prenatal Testing (NIPT) Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Test Type
    • 10.2.3. By Method
    • 10.2.4. By Application
    • 10.2.5. By End User
    • 10.2.6. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By Test Type
        • 10.3.1.2.3. By Method
        • 10.3.1.2.4. By Application
        • 10.3.1.2.5. By End User
    • 10.3.2. Saudi Arabia Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By Test Type
        • 10.3.2.2.3. By Method
        • 10.3.2.2.4. By Application
        • 10.3.2.2.5. By End User
    • 10.3.3. UAE Non-invasive Prenatal Testing (NIPT) Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By Test Type
        • 10.3.3.2.3. By Method
        • 10.3.3.2.4. By Application
        • 10.3.3.2.5. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Global Oral Clinical Nutrition Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Service Offerings
  • 15.3. Recent Developments
  • 15.4. Key Personnel
  • 15.5. SWOT Analysis
    • 15.5.1. YOURGENE HEALTH Plc
    • 15.5.2. Illumina, Inc.
    • 15.5.3. Natera, Inc.
    • 15.5.4. F.Hoffman La Roche Ltd.
    • 15.5.5. Perkin Elmer Inc.
    • 15.5.6. Laboratory Corporation of America Holdings
    • 15.5.7. Eurofins LifeCodex GmbH
    • 15.5.8. Progenity, Inc.
    • 15.5.9. Genesis Genetics
    • 15.5.10. Quest Diagnostics Incorporated

16. Strategic Recommendations

17. About Us & Disclaimer